Publicaciones en las que colabora con Salvador Martín Algarra (17)

2016

  1. Bringing model-based prediction to oncology clinical practice: A review of Pharmacometrics principles and applications

    Oncologist, Vol. 21, Núm. 2, pp. 220-232

2015

  1. Early prediction of disease progression in small cell lung cancer: Toward model-based personalized medicine in oncology

    Cancer Research, Vol. 75, Núm. 12, pp. 2416-2425

2014

  1. A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients

    AAPS Journal, Vol. 16, Núm. 3, pp. 609-619

  2. Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy

    PLoS ONE, Vol. 9, Núm. 2

  3. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins

    Clinical Cancer Research, Vol. 20, Núm. 22, pp. 5697-5707

2012

  1. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

2007

  1. Carcinoma microcítico de pulmón

    Revista de medicina, Vol. 51, Núm. 2, pp. 7-13

  2. Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy

    Oncologist, Vol. 12, Núm. 9, pp. 1151-1155

  3. Small-cell lung cancer

    Revista de medicina de la Universidad de Navarra, Vol. 51, Núm. 2, pp. 7-13

2005

  1. Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung center: Two case reports and a review of the literature

    Clinical Lung Cancer, Vol. 7, Núm. 2, pp. 138-140

  2. Assessment of the value of confirming responses in clinical trials in oncology

    European Journal of Cancer, Vol. 41, Núm. 11, pp. 1528-1532

2004

  1. ERK 1/2 is activated in non-small-cell lung cancer and associated with advanced tumours

    British Journal of Cancer, Vol. 90, Núm. 5, pp. 1047-1052

  2. Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancer

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 27, Núm. 3, pp. 299-303

  3. Preliminary experience with intensity modulated radiation therapy for abdominopelvic tumor sites: a comparison with 3D radiotherapy plans

    Revista de oncología: Publicación oficial de la Federación de Sociedades Españolas de Oncología y del Instituto Nacional de Cancerología de México, Vol. 6, Núm. 7, pp. 415-423

2003

  1. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer

    Oncology, Vol. 64, Núm. 1, pp. 28-35

2002

  1. Radiation therapy after high-dose chemotherapy with peripheral blood stem cell support for high-risk breast cancer

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 25, Núm. 4, pp. 347-353

2001

  1. Pulmonary embolism after local urokinase instillation in a Hickman catheter [3]

    Bone Marrow Transplantation